The Trump administration has decided not to go forward with a proposal for Medicare and Medicaid to cover high-demand obesity ...

The Trump administration did away with a Biden-era proposal to allow Medicare to start paying for weight loss drugs such as ...

Eli Lilly & Co.’s shares fell Monday morning after the Trump administration spiked a plan late last week to pay for obesity drugs for Medicare patients.

Doctors say it’s not uncommon for patients to not lose weight on the GLP-1 drugs, even if celebrities are seemingly shedding dozens of pounds. Julia Musto spoke to people frustrated that they are part ...

Danish drugmaker Novo Nordisk is looking at an early launch of its blockbuster weight-loss drug Wegovy in India to better ...

This decision is a blow for Eli Lilly and Novo Nordisk, who had both previously endorsed the proposed expansion.

To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

Eli Lilly has launched weight-loss drug Mounjaro in India, priced at Rs 3,500 per injection for a 2.5mg dose. Will high costs ...

At least 14 states already cover the cost of GLP-1 medications for obesity treatment for patients on Medicaid. Indiana is not ...

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage ...

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.